Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 2/20 | 0.44 |
| ▸ | IGF1R | P08069 | 4/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906638 | 1.00 | EGFR (0.49) | EGFRJAK2JAK3CCNE1CDK2 | |
| SCHEMBL23906540 | 0.86 | EGFR (0.55) | EGFRJAK2JAK3CCNE1CDK2 | |
| SCHEMBL30086622 | 0.86 | EGFR (0.55) | EGFRJAK2JAK3CCNE1CDK2 | |
| SCHEMBL30086282 | 0.85 | JAK2 (0.51) | EGFRJAK2JAK3PDGFRBPDGFRA | |
| SCHEMBL23906621 | 0.85 | JAK2 (0.51) | EGFRJAK2JAK3PDGFRBPDGFRA | |
| SCHEMBL23906262 | 0.85 | EGFR (0.51) | EGFRJAK2JAK3PDGFRBPDGFRA | |
| SCHEMBL30086709 | 0.85 | EGFR (0.51) | EGFRJAK2JAK3PDGFRBPDGFRA | |
| SCHEMBL23906597 | 0.84 | IGF1R (0.62) | EGFRJAK2JAK3CCNE1CDK2 | |
| SCHEMBL30086456 | 0.84 | IGF1R (0.62) | EGFRJAK2JAK3CCNE1CDK2 | |
| SCHEMBL23906605 | 0.82 | BRD4 (0.51) | EGFRJAK2JAK3PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | EGFR 545/4885JAK2 1187/4885JAK3 1474/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | EGFR 545/4885JAK2 1187/4885JAK3 1474/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | EGFR 545/4885JAK2 1187/4885JAK3 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.